Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SlovakiaBack to Slovakia

Clinical trials in Poprad

32 clinical trials in Poprad, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Poprad at a glance
32
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

32 trials in Poprad

Open in trial search

Colorectal cancer+1

Recruiting

Study of NGM120 in patients with colorectal cancer and cancer cachexia: Evaluating effects on body weight

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST GDNF FAMILY RECEPTOR ALPHA-LIKE
  • Sponsor:Ngm Biopharmaceuticals Inc.

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Sjogren's syndrome

Recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Heart failure with reduced ejection fraction

Recruiting

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Neovascular age-related macular degeneration

Recruiting

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Diabetic retinal oedema

Recruiting

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Recruiting

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Neoplasm malignant+1

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Type IIa hyperlipidaemia

Recruiting

Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Other cities in Slovakia

The busiest research cities in the country

All 92 cities in Slovakia

Clinical research in Poprad

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on non-small cell lung cancer treatments and advanced asthma management. Studies evaluate novel combination therapies and long-term disease control approaches.

  • Advanced NSCLC Treatments
  • Severe Asthma Management
  • Targeted Lung Therapies

Multiple trials investigating breakthrough treatments for patients with specific genetic markers and varying disease stages.

02 Rheumatology

Comprehensive studies examining new treatments for psoriatic arthritis, with particular focus on biologic therapies and disease-modifying treatments.

  • Axial Disease Management
  • Novel Biologic Therapies
  • DMARD-Resistant Cases

Research aims to improve symptom control and quality of life for patients with various forms of arthritis.

03 Oncology

Groundbreaking research in advanced melanoma and colorectal cancer, exploring targeted therapies and combination treatments for specific genetic mutations.

  • Metastatic Melanoma
  • Colorectal Cancer
  • Targeted Therapies

Studies focus on personalized treatment approaches based on genetic markers and disease characteristics.

04 Metabolic Disorders

Research addressing familial hypercholesterolemia and type 2 diabetes, investigating innovative treatment approaches and long-term disease management strategies.

  • Cholesterol Management
  • Diabetes Control
  • Metabolic Optimization

Trials aim to improve treatment outcomes and patient care in chronic metabolic conditions.

Back to SlovakiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.